Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2020 1
2021 2
2022 2
2023 2
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G; STAMPEDE collaborators. Leone G, et al. JAMA Oncol. 2025 Feb 27;11(4):426-9. doi: 10.1001/jamaoncol.2024.7051. Online ahead of print. JAMA Oncol. 2025. PMID: 40014335
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW; STAMPEDE investigators. Gillessen S, et al. Lancet Oncol. 2025 Aug;26(8):1018-1030. doi: 10.1016/S1470-2045(25)00231-1. Epub 2025 Jul 7. Lancet Oncol. 2025. PMID: 40639383 Free PMC article. Clinical Trial.
Prehabilitation of Patients With Oesophageal Malignancy Undergoing Peri-Operative Treatment (Pre-EMPT): Outcomes From a Prospective Controlled Trial.
Bott R, Zylstra J, Knight W, Whyte GP, Lane AM, Moss C, Browning M, Lagergren J, Van Hemelrijck M, Davies AR; Pre‐EMPT study group including the following co‐authors. Bott R, et al. J Surg Oncol. 2025 Jun;131(8):1508-1520. doi: 10.1002/jso.28079. Epub 2025 Jan 29. J Surg Oncol. 2025. PMID: 39878357 Free PMC article. Clinical Trial.
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Popat S, Januszewski A, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Morris C, Ngai Y, Hughes L, Hackshaw A, Wilson W. Popat S, et al. Among authors: cominos m. Br J Cancer. 2025 Feb;132(3):245-252. doi: 10.1038/s41416-024-02901-6. Epub 2024 Dec 5. Br J Cancer. 2025. PMID: 39639088 Free PMC article. Clinical Trial.
REsolution of Symptoms afTer Oesophago-gastric cancer REsection delphi (RESTOREd)-standardizing the definition, investigation and management of gastrointestinal symptoms and conditions after surgery.
Byrne BE, Siaw-Acheampong K, Evans O, Taylor J, Huddy F, Nilsson M, Griffiths EA, Low D, Gossage J, Dunn J, Zeki S, Markar S, Avery K, Blazeby JM, Cockbain A, Moss C, van Hemelrijck M, Andreyev J, Davies AR; RESTORE Delphi study group. Byrne BE, et al. Br J Surg. 2024 Nov 27;111(12):znae286. doi: 10.1093/bjs/znae286. Br J Surg. 2024. PMID: 39657739
Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.
Bott RK, Beckmann K, Zylstra J, Wilkinson MJ, Knight WRC, Baker CR, Kelly M, Maisey N, Qureshi A, Sevitt T, Van Hemelrijck M, Smyth EC, Allum WH, Lagergren J, Gossage JA, Cunningham D, Davies AR; Guy's and St Thomas' Oesophagogastric Research Group. Bott RK, et al. Br J Surg. 2020 Dec;107(13):1801-1810. doi: 10.1002/bjs.11864. Epub 2020 Sep 29. Br J Surg. 2020. PMID: 32990343
15 results